相关实验视频
Updated: Mar 11, 2026

02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
5.9K
德尔摩芬阻断了对芬太尼尔静脉注射的呼吸暂停反应
Jianguo Zhuang1, Xiuping Gao1, Shan Shi1
1Department of Physiology, Lovelace Biomedical Research Institute, Albuquerque, NM 87108, United States of America.
Toxicology and applied pharmacology
|March 9, 2026
概括
德尔摩芬预治疗通过使mu1阿片类受体 (μ1-ORs) 不敏感,有效地阻断芬太尼尔诱导的呼吸暂停. 这一发现表明了潜在的治疗策略,以防止致命的呼吸系统抑郁因芬太尼过量服用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 呼吸系统生理学 呼吸系统生理学
背景情况:
- 通过静脉注射玻尿酸注射的芬太尼过量是阿片类药物诱导死亡的主要原因.
- 芬太尼触发了致命的,持续的呼吸暂停,由mu1阿片类受体 (μ1-ORs) 介导.
- 目前缺乏对芬太尼诱导的呼吸抑制有效的对策.
研究的目的:
- 调查甲状腺素预治疗是否可以预防或减少芬太尼诱导的呼吸暂停.
- 探索mu1阿片类受体 (μ1-ORs) 在芬太尼和德尔摩芬诱导的心肺呼吸系统影响中的作用.
主要方法:
- 在麻醉的老鼠中,对静脉注射甲状腺和芬太尼的心肺呼吸系统反应进行了评估.
- 评估了纳洛克萨纳 (一种μ1-OR抗剂) 对皮肤色素反应的影响.
- 研究了dermorphin对芬太尼诱导的呼吸暂停和相反的治疗前影响.
主要成果:
- 德尔摩芬和芬太尼都通过μ1-OR激活诱导了即时的呼吸暂停,但与德尔摩芬的恢复速度更快.
- 甲状腺素诱导的呼吸暂停在单次注射后显示无敏化,与芬太尼不同.
- 甲状腺素预治疗成功地阻断了芬太尼诱导的呼吸暂停,而芬太尼预治疗没有影响甲状腺素反应.
结论:
- 德尔摩芬预治疗可以预防芬太尼诱导的呼吸暂停,可能是通过μ1-OR脱敏.
- 这种机制为管理芬太尼过量服用提供了潜在的治疗干预措施.
- 针对μ1-OR脱敏可能对开发有效的阿片类药物过量治疗至关重要.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
Parenteral Anesthetics: Overview
849
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
849
Opioid Analgesics: Morphine and Other Natural Cogeners
1.3K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.3K
Depolarizing Blockers: Pharmocokinetics
687
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
687
Opioid Receptors: Overview
5.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K

